167 related articles for article (PubMed ID: 9596412)
1. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype.
Montine KS; Reich E; Neely MD; Sidell KR; Olson SJ; Markesbery WR; Montine TJ
J Neuropathol Exp Neurol; 1998 May; 57(5):415-25. PubMed ID: 9596412
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4.
Montine KS; Olson SJ; Amarnath V; Whetsell WO; Graham DG; Montine TJ
Am J Pathol; 1997 Feb; 150(2):437-43. PubMed ID: 9033259
[TBL] [Abstract][Full Text] [Related]
3. 4-hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease.
Montine KS; Kim PJ; Olson SJ; Markesbery WR; Montine TJ
J Neuropathol Exp Neurol; 1997 Aug; 56(8):866-71. PubMed ID: 9258256
[TBL] [Abstract][Full Text] [Related]
4. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal.
Pedersen WA; Chan SL; Mattson MP
J Neurochem; 2000 Apr; 74(4):1426-33. PubMed ID: 10737598
[TBL] [Abstract][Full Text] [Related]
5. Crosslinking of apolipoprotein E by products of lipid peroxidation.
Montine TJ; Huang DY; Valentine WM; Amarnath V; Saunders A; Weisgraber KH; Graham DG; Strittmatter WJ
J Neuropathol Exp Neurol; 1996 Feb; 55(2):202-10. PubMed ID: 8786379
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E and oxidative stress in brain with relevance to Alzheimer's disease.
Butterfield DA; Mattson MP
Neurobiol Dis; 2020 May; 138():104795. PubMed ID: 32036033
[TBL] [Abstract][Full Text] [Related]
7. 4-Hydroxynonenal immunoreactivity is increased in human hippocampus after global ischemia.
McKracken E; Graham DI; Nilsen M; Stewart J; Nicoll JA; Horsburgh K
Brain Pathol; 2001 Oct; 11(4):414-21. PubMed ID: 11556686
[TBL] [Abstract][Full Text] [Related]
8. Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's disease.
Fukuda M; Kanou F; Shimada N; Sawabe M; Saito Y; Murayama S; Hashimoto M; Maruyama N; Ishigami A
Biomed Res; 2009 Aug; 30(4):227-33. PubMed ID: 19729853
[TBL] [Abstract][Full Text] [Related]
9. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.
Markesbery WR; Lovell MA
Neurobiol Aging; 1998; 19(1):33-6. PubMed ID: 9562500
[TBL] [Abstract][Full Text] [Related]
10. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype.
Ramassamy C; Averill D; Beffert U; Bastianetto S; Theroux L; Lussier-Cacan S; Cohn JS; Christen Y; Davignon J; Quirion R; Poirier J
Free Radic Biol Med; 1999 Sep; 27(5-6):544-53. PubMed ID: 10490274
[TBL] [Abstract][Full Text] [Related]
11. A quantitative and immunohistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease.
Hesse C; Bogdanovic N; Davidsson P; Blennow K
Dement Geriatr Cogn Disord; 1999; 10(6):452-9. PubMed ID: 10559559
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis.
Richey PL; Siedlak SL; Smith MA; Perry G
Biochem Biophys Res Commun; 1995 Mar; 208(2):657-63. PubMed ID: 7695621
[TBL] [Abstract][Full Text] [Related]
13. [The role of apolipoprotein E in the pathogenesis of Alzheimer disease].
Okuizumi K
Nihon Rinsho; 1999 Dec; 57(12):2673-7. PubMed ID: 10638195
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls.
Pirttilä T; Soininen H; Heinonen O; Lehtimäki T; Bogdanovic N; Paljärvi L; Kosunen O; Winblad B; Riekkinen P; Wisniewski HM; Mehta PD
Brain Res; 1996 May; 722(1-2):71-7. PubMed ID: 8813351
[TBL] [Abstract][Full Text] [Related]
15. APOE genotype and cholesterol levels in lewy body dementia and Alzheimer disease: investigating genotype-phenotype effect on disease risk.
Borroni B; Grassi M; Costanzi C; Archetti S; Caimi L; Padovani A
Am J Geriatr Psychiatry; 2006 Dec; 14(12):1022-31. PubMed ID: 16956959
[TBL] [Abstract][Full Text] [Related]
16. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease.
Sayre LM; Zelasko DA; Harris PL; Perry G; Salomon RG; Smith MA
J Neurochem; 1997 May; 68(5):2092-7. PubMed ID: 9109537
[TBL] [Abstract][Full Text] [Related]
17. ApoE genotype accounts for the vast majority of AD risk and AD pathology.
Raber J; Huang Y; Ashford JW
Neurobiol Aging; 2004; 25(5):641-50. PubMed ID: 15172743
[TBL] [Abstract][Full Text] [Related]
18. Isoform-specific modification of apolipoprotein E by 4-hydroxynonenal: protective role of apolipoprotein E3 against oxidative species.
Abeer MI; Abdulhasan A; Haguar Z; Narayanaswami V
FEBS J; 2023 Jun; 290(11):3006-3025. PubMed ID: 36661393
[TBL] [Abstract][Full Text] [Related]
19. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients.
Montine TJ; Markesbery WR; Zackert W; Sanchez SC; Roberts LJ; Morrow JD
Am J Pathol; 1999 Sep; 155(3):863-8. PubMed ID: 10487843
[TBL] [Abstract][Full Text] [Related]
20. Role of 4-hydroxy-2-nonenal (HNE) in the pathogenesis of alzheimer disease and other selected age-related neurodegenerative disorders.
Di Domenico F; Tramutola A; Butterfield DA
Free Radic Biol Med; 2017 Oct; 111():253-261. PubMed ID: 27789292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
